Unknown Manufacturer
TMV-083 is an attenuated live virus COVID-19 vaccine candidate which employs the measles vaccine as a vector. It expresses a spike protein antigen from SARS-CoV-2.
TMV-083 is an attenuated live virus COVID-19 vaccine candidate which employs the measles vaccine as a vector. It expresses a spike protein antigen from SARS-CoV-2.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
